Reading through the report in more detail the following was of particular interest. FTO levels appear to be x3 times the pre-radio therapy levels. this could easily result in benefits with all Radio-therapies + any cancer resistance caused by ferroptosis. As with Decitabine, the treatment itself upregulates FTO and thus aids in Zantrene wiping out the cancer via FTO inhibition. From the study a similar thing occurs with Radio-therapy and not just ferroptosis caused by NPC.
Source: m6A demethylase FTO renders radioresistance of nasopharyngeal carcinoma via promoting OTUB1-mediated anti-ferroptosis - ScienceDirect
Whilst we await the Cardio protect results, I can only speculate on the MOA. But if this extends to other treatments beyond Dox and Carfilzomib that would be astonishing. Also cardio-renal indications can benefit greatly from cardio protection - if Zantrene's MOA works across the board.
The list goes on and on, is this what immuno-therapy research first started out like?
General Comments / Chat, page-6075
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $246.3M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |